echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Biomedical market expands import substitution trend continues

    Biomedical market expands import substitution trend continues

    • Last Update: 2017-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [market analysis of chinapharma.com] according to the reports of marketsandmarkets, the global market size of contrast agents in 2016 is estimated to be 4.45 billion US dollars, which is expected to reach 5.44 billion US dollars by 2021, with CAGR of 4.1% At present, the global market is dominated by X-ray contrast agents, accounting for nearly 80%, of which iohexol, iodopanol and ioksacol are the top three in sales Contrast media has a long history, and the international market tends to be mature: the use of contrast media is closely related to imaging equipment, which can be divided into three categories: X-ray, magnetic resonance and ultrasound contrast media Its development can be traced back to the end of the 19th century, and technological progress is the main driving force of product iteration Due to the stable use of contrast media in developed countries such as Europe and the United States, the international market is becoming more and more mature Rapid development of domestic market and continuous import substitution trend: according to IMS statistics, China's contrast agent market scale increased from 2.3 billion yuan in 2010 to 6.4 billion yuan in 2016, with CAGR of 18.6%, higher than the overall growth rate of the pharmaceutical industry The pattern of domestic products is similar to that of the world In 2012, the proportion of X-ray contrast agents reached 85.93% From the perspective of enterprises, the competition pattern is stable and the import substitution is the general trend The proportion of foreign capital and joint ventures in the sample hospital market decreased from more than 55% in 2012 to about 43% in 2016 We believe that driven by industry expansion, import substitution and product upgrading, the contrast agent industry in China will maintain a growth rate of about 15% in the future Related listed companies in contrast agent industry: Hengrui pharmaceutical has achieved 37% CAGR since 2011 by virtue of two major varieties, i.e iodofol and i.k.s.a We expect that in the next 2-3 years, the growth rate of iofool will be maintained at about 15%, and the growth rate of ioxanol will be 30% - 40%, maintaining the "recommended" rating; Beilu pharmaceutical industry has a wide range of contrast agents with complete specifications, and the CAGR since 2009 will be 20.94% We expect that the growth rate of meglumine gadolinoate and iohexol, as the main source of income, will be stable, and we are optimistic about the bidding volume of iodipatol and ioxaitol, and maintain the "recommended" rating; Stellite mainly focuses on the production of X-ray contrast agent APIs, and its performance is highly correlated with the performance of downstream preparations At present, the company is a domestic enterprise of iodipatol and only iodixaitol API The bidding volume of two new varieties may have an impact on its performance Original title: biomedical industry investment report: rapid development of domestic market, import substitution trend, continue to teach you to use app (Pharma) and seize the opportunity of pharmaceutical machinery
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.